Julie Kanter, MD

Patients with sickle cell disease may be at higher risk for certain COVID-19 complications and death, according to results of two studies presented at ASH Annual Meeting and Exposition.

ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — The maximum tolerated dose of hydroxyurea appeared noninferior to chronic transfusions for maintaining transcranial Doppler velocities and preventing stroke in high-risk children with sickle cell anemia, according to findings from the TWiTCH trial presented during the plenary session at the ASH Annual Meeting and Exposition.